Form 4: United Therapeutics CEO Exercises, Sells Shares

Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp, exercised stock options and sold common stock shares as part of a pre-arranged 10b5-1 trading plan.

Summary

• Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp (UTHR), engaged in transactions involving the exercise of stock options and subsequent sale of common stock on November 18 and 19, 2025.
• On November 18, 2025, Rothblatt exercised options to acquire 4,000 shares of common stock at an exercise price of $120.26 per share.
• Immediately following the option exercise on November 18, 2025, Rothblatt sold a total of 4,000 shares of common stock in three separate transactions at weighted average prices of $470.5333, $472.595, and $475.095 per share.
• On November 19, 2025, Rothblatt again exercised options to acquire 4,000 shares of common stock at an exercise price of $120.26 per share.
• Following the option exercise on November 19, 2025, Rothblatt sold a total of 4,000 shares of common stock in two separate transactions at weighted average prices of $474.2178 and $474.95 per share.
• All reported transactions were conducted under a pre-arranged Rule 10b5-1 trading plan established on May 2, 2025.
• After these transactions, Rothblatt directly holds 130 shares of common stock and indirectly holds 166 shares by spouse, 324,518 shares by a family trust, 258,117 shares by another family trust, 45,596 shares by spouse (via family trusts), and 15,962 shares by a family trust.
• The remaining stock options beneficially owned after these transactions total 82,000, with an exercise price of $120.26 and an expiration date of March 15, 2026.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The transactions are routine insider sales under a pre-arranged 10b5-1 plan, which is a common practice for executives to manage their equity compensation. While it involves selling shares, the pre-planned nature mitigates any negative implications regarding management's confidence in the company.

Positives

• The executive is realizing value from previously granted stock options, indicating a successful compensation structure.
• The sale prices of the common stock (ranging from $470.53 to $475.09) are significantly higher than the exercise price ($120.26), demonstrating substantial gains for the executive.

Negatives

• Insider sales, even under a 10b5-1 plan, can sometimes be perceived by some investors as a lack of confidence, though this is mitigated by the pre-arranged nature.

Future Outlook

The pre-arranged 10b5-1 trading plan, established on May 2, 2025, is set to continue until the earlier of the exhaustion of a tranche of 294,000 stock options expiring March 15, 2026, or December 31, 2025. This indicates a planned, systematic approach to option exercise and share disposition by the executive.

Industry Context

This Form 4 filing details routine insider transactions under a pre-arranged plan and does not provide information relevant to broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive could be viewed with slight caution, but the pre-arranged 10b5-1 plan typically minimizes concerns about opportunistic selling. The transactions represent the executive realizing value from their compensation.

Next Steps

• The pre-arranged 10b5-1 trading plan will continue until the earlier of the exhaustion of a tranche of 294,000 stock options (expiring March 15, 2026) or December 31, 2025.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions under a pre-arranged 10b5-1 plan. It does not contain new information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The transactions are part of an executive's personal financial planning and compensation realization, which is a normal occurrence for publicly traded companies. Therefore, a "hold" recommendation is appropriate as this filing alone does not provide a basis for a "buy" or "sell" decision.

Keywords

United Therapeutics, UTHR, Martine Rothblatt, insider trading, Form 4, stock options, 10b5-1 plan, common stock, executive compensation, share sale